Harrow Health Inc is trading 7% up at $35.81 following the re-launch of its prescriptive VKC eye treatment, VERKAZIA, which has sparked renewed investor optimism regarding its ophthalmic franchise.
- The company is focusing on securing a dependable supply and reducing access barriers for this vernal keratoconjunctivitis therapy.
- The stock is currently outperforming a slightly weaker broader market as traders react to the product-focused update.